地西他滨联合或不联合羟基脲对比羟基脲治疗晚期增殖性CMML的随机III期研究
该数据集来自clinicaltrials.gov，主题为MDS，收录一项随机III期研究，比较地西他滨联合或不联合羟基脲（HY）与单用HY治疗晚期增殖性CMML
基本信息
资源简介
地西他滨联合或不联合羟基脲对比羟基脲治疗晚期增殖性CMML的随机III期研究
该数据集来自clinicaltrials.gov，主题为MDS，收录一项随机III期研究，比较地西他滨联合或不联合羟基脲（HY）与单用HY治疗晚期增殖性CMML。源站描述涉及ARM A中地西他滨20 mg/m2静脉给药方案、治疗延迟条件、肾功能或肝功能异常处理、持续4级血小板或中性粒细胞减少的骨髓评估要求，以及别嘌呤醇300mg/d的使用。可用于了解该试验的用药方案与安全性管理信息（来源 clinicaltrials.gov）。
【数据内容】
源站描述（机器翻译，仅供参考）：条件：MDS。ARM A：地西他滨（DAC）地西他滨（DAC）将每28天静脉注射20 mg/m2，每日一次，连续5天。研究者可自行决定延迟治疗（最多至D56），用于发热性中性粒细胞减少（≥ 38.5°C；绝对中性粒细胞计数[ANC] < 1,000/μL）、伴有3至4级中性粒细胞减少（ANC < 1,000/μL）的临床和/或微生物学感染，或伴有4级血小板减少（< 25,000 platelets/μL）的出血。如果发生肾功能或肝功能异常，将停止治疗直至缓解，若异常持续超过4天则暂停。D49后持续4级血小板减少或中性粒细胞减少将强制进行骨髓评估。治疗将持续至达到事件。事件及因此的研究退出仅在研究者和试验委员会达成一致后确认。别嘌呤醇300mg/d将开始于
【主题与分类】
主题标签：MDS。本站分类：消化系统疾病。
【获取与许可】
源站页面：https://clinicaltrials.gov/study/NCT02214407
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站：https://clinicaltrials.gov/study/NCT02214407
标准获取流程：
- 访问源站链接，注册/登录账号；
- 进入数据集详情页，按页面指引申请权限或直接下载；
- 部分平台提供 SDK，例如：
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: MDS. ARM A: DECITABINE (DAC) Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Treatment will be delayed at the discretion of the investigator (up to D56) for febrile neutropenia (≥ 38.5°C; absolute neutrophil count [ANC], < 1,000/μL), clinical and/or microbiologic infection with grade 3 to 4 neutropenia (ANC < 1,000/μL), or hemorrhage with grade 4 thrombocytopenia (< 25,000 platelets/μL). If renal or hepatic dysfunction occurs, treatment will be stopped until resolution or withheld if dysfunction persists more than 4 days. Persistent grade 4 thrombocytopenia or neutropenia beyond D49 will mandate bone marrow evaluation. Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee. Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L. ARM B: HYDROXYUREA (HY) Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients. Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee. This is intended to prevent early dropout, notably in the HY arm. Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 109/L (if initially below 100 X 109L). HY will be discon
数据加载示例（图像类）
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
需要用于商业化训练或医疗器械注册（NMPA/FDA）？
公开数据往往缺乏完整的病理回证与专家标注。千方医数集依托陕川双基地与超十家三甲医院直连，提供完全合规、去标识化、支持注册级质控的专病数据集交易服务。
